Stockwinners Market Radar for July 27, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
XLE... | Hot Stocks17:35 EDT Week ending ETF Scorecard: Energy recovers, Technology sinks - S&P500 SECTORS: Energy (XLE) up 2.3%... Industrials (XLI) up 2.1%... Financials (XLF) up 2.1%... Materials (XLB) up 1.7%... Health Care (XLV) up 1.4%... Consumer Staples (XLP) up 1.0%... Utilities (XLU) up 0.7%... Telecom (IYZ) down 0.2%... Consumer Discretionary (XLY) down 0.5%... Real Estate (IYR) down 0.6%... Technology (XLK) down 1.0%. COMMODITY: Gold (GLD) down 0.6%... Silver (SLV) down 0.1%... Copper (CPER) up 1.5%... Crude Oil (USO) up 1.2%... Natural Gas (UNG) up 1.9%. FIXED INCOME: High Yield (HYG) up 0.3%... Investment Grade (LQD) up 0.3%... Long-term Treasury (TLT) down 1.1%... Mid-term Treasury (IEF) down 0.4%... Short-term Treasury (SHY) down 0.1%. STRATEGY: Value (IWD) up 1.3%... Growth (IWF) down 0.5%.
|
ADBE | Hot Stocks17:27 EDT Adobe exec sells 15,000 common shares - In a regulatory filing, Adobe Systems EVP and GM, Experience Cloud Bradley Rencher disclosed the sale of 15,000 common shares of the company at a price of $262.3448 per share.
|
NSC | Hot Stocks17:21 EDT Norfolk Southern increases quarterly dividend 11% - Norfolk Southern Corporation announced that its board approved an 11% increase in its quarterly dividend on the company's common stock, to 80c per share from 72c per share. Combined with the 18% dividend increase in Q1, Norfolk Southern has increased its dividend by 29% in 2018.
|
CCB | Hot Stocks17:21 EDT EJF Capital reports 7.4% passive stake in Coastal Financial
|
LDOS | Hot Stocks17:11 EDT Leidos awarded $170.8M U.S. Defense Department contract - Leidos was awarded a base year plus four option years cost-plus award fee contract to provide linguist operations support for the Defense Intelligence Agency's National Media Exploitation Center located in Bethesda, Maryland. The contract has a start date of Aug. 1, 2018, with a potential end date of July 31, 2023, and a ceiling of $170,804,015 if all options are exercised. Through this award, DIA will procure foreign language translation services and content exploitation of captured, seized or otherwise acquired digital media and documents. Work will be performed primarily in Bethesda, Maryland.
|
PZZA | Hot Stocks17:02 EDT Papa John's appoints Olivia Kirtley as board chair - Papa John's announced that lead independent director Olivia Kirtley has been appointed chair of the company's board by a unanimous vote of the board. In addition, the company stated that the Corporate Governance and Nominating Committee of the board has been conducting a search for additional independent directors and intends to engage with Papa John's shareholders as part of this process. Kirtley stated, "The independent directors of the Papa John's board are committed to serving the best interests of the company, our shareholders and other stakeholders. The establishment of the board's independent Special Committee and the ongoing cultural audit and investigation are among numerous steps underway to ensure that equity, inclusion, diversity and respect are upheld throughout the organization. Many stakeholders, including team members, franchisees and shareholders, have expressed their support for the actions we are taking. We appreciate this support and value the feedback we have received. The independent members of the board and leadership will continue to engage with shareholders and other stakeholders to hear their perspectives and ideas, including on board composition, so that these views can be considered in our work to move forward."
|
CGIX | Hot Stocks16:46 EDT Iliad Research & Trading reports 9.99% passive stake in Cancer Genetics
|
NWN | Hot Stocks16:45 EDT Northwest Natural Gas CAO Doolittle to retire - NW Natural's board of directors acknowledged Lea Anne Doolittle's intent to retire as an officer at the end of December, following 18 years of service with the company. Doolittle began her career at NW Natural as vice president of Human Resources, and then was promoted to senior vice president and Chief Administrative Officer where she oversees Human Resources, Information Technology, Safety, Facilities, Emergency Management/Business Continuity, Project Management, Labor Relations, and Security.
|
JSYN | Hot Stocks16:37 EDT K2 Principal Fund reports 6.58% passive stake in Jensyn Acquisition
|
WUBA | Hot Stocks16:35 EDT Genesis Asset Managers reports 5.48% passive stake in 58.com
|
USDP | Hot Stocks16:20 EDT USD Partners increases quarterly distribution 0.7% - USD Partners LP announced that the board of its general partner declared a quarterly cash distribution of 35.5c per unit for Q2, representing an increase 0.7% over the prior quarter and 4.4% over Q2 of 2017. The distribution is payable on August 14 to unitholders of record at the close of business on August 7.
|
CNXM | Hot Stocks16:16 EDT CNX Midstream Partners increases quarterly distribution 3.6% - CNX Midstream Partners LP announced that the board of its general partner, CNX Midstream GP LLC, has declared a cash distribution of 33.61c per unit with respect to Q2. The distribution will be made on August 14 to unitholders of record as of the close of business on August 7. The distribution, which equates to an annual rate of $1.3444 per unit, represents an increase of 3.6% over the prior quarter, and an increase of 15% over the distribution paid with respect to Q2 of 2017.
|
ARLP | Hot Stocks16:16 EDT Alliance Resource Partners raises quarterly distribution to 52c per unit - Payable on August 14 to all unitholders of record as of the close of trading on August 7.
|
NITE | Hot Stocks16:13 EDT Redmile Group reports 6.1% passive stake in Nightstar Therapeutics
|
LAD | Hot Stocks16:12 EDT Abrams Capital reports 5.5% passive stake in Lithia Motors
|
SPY... | Hot Stocks16:10 EDT Weekly CFTC Commitment of Traders highlights - S&P500 net long 3.6K contracts, down 1.9K from prior week and a 4-week low in net longs... 10-YEAR U.S. TREASURY net short 509.5K contracts, up 40.3K from prior week and a multi-year high in net shorts... U.S. DOLLAR INDEX net long 25.3K contracts, up 6.4K from prior week and a 13-month high in net longs... EURO net long 29.6K contracts, up 8.2K from prior week and a 3-week high in net longs... BRITISH POUND net short 46.7K contracts, up 7.9K from prior week and a 10-month high in net shorts... JAPANESE YEN net short 73.8K contracts, up 15.1K from prior week and a 4-month high in net shorts... CANADIAN DOLLAR net short 44.5K contracts, down 3.0K from prior week and a 4-week low in net shorts... CRUDE OIL net long 610.5K contracts, down 20.8K from prior week and a 5-week low in net longs... GOLD net long 48.6K contracts, down 9.2K from prior week and a 18-month low in net longs... COPPER net long 9.4K contracts, up 0.3K from prior week and the first rise in net longs in 6 weeks.
|
AVA | Hot Stocks16:06 EDT Avista requests natural gas rate decrease for Oregon customers - Avista's customers in Oregon would see a decrease in their natural gas rates effective Nov. 1, 2018 if the Public Utility Commission of Oregon approves the company's annual rate adjustment filings. These filings have no impact on the company's earnings and are not related to the proposed acquisition of Avista by Hydro One.
|
PTCT | Hot Stocks16:03 EDT D.E. Shaw reports 5.0% passive stake in PTC Therapeutics
|
HOLX NERV | Hot Stocks16:03 EDT Hologic awarded $4.8M in patent infringement suit against Minerva - Hologic (HOLX) announced that a jury in the U.S. District Court for the District of Delaware awarded Hologic $4.8M in damages for Minerva Surgical's (NERV) infringement of two Hologic patents related to endometrial ablation technology. On June 28, 2018, the Court ruled that Minerva's endometrial ablation system infringes U.S. Patents 6,872,183 and 9,095,348. The Court also rejected all of Minerva's defenses to infringement. As a result of these decisions, Hologic will seek an injunction prohibiting Minerva from further manufacturing or selling the infringing device in the United States. Damages will continue to accrue until Minerva ceases its infringing conduct. In November 2015, Hologic brought suit against Minerva alleging that Minerva's endometrial ablation system infringes several Hologic patents. The patents relate to technology used in the company's NovaSure endometrial ablation procedure, a market-leading treatment for abnormal uterine bleeding. In 2004, Hologic acquired the patents through its acquisition of Novacept, Inc. Former Novacept executive Csaba Truckai founded Minerva four years later. Minerva then developed and commercialized its endometrial ablation device, which the Court found incorporated the same patented technology that Novacept sold to Hologic.
|
DUK | Hot Stocks15:37 EDT Duke Energy proposes rate increase in South Carolina - Duke Energy Carolinas today made its annual filing with the Public Service Commission of South Carolina for the costs associated with the purchase of fuel to generate electricity at its power plants. The PSCSC reviews fuel costs and adjusts the fuel component of customer rates accordingly. By law, the company makes no profit from the fuel component of rates. If approved, the total monthly impact for a typical residential customer in South Carolina using 1,000 kilowatt-hours (kWh) per month would be an increase of $4.75. Commercial customers would see an average increase in the fuel charge of about 6.1%, and industrial customers would receive an average increase of about 8.0%. Natural gas prices rose this winter due to heavy demand for residential, commercial, and industrial usage to meet customer energy needs during prolonged freezing conditions. These increased prices, coupled with high demand, contributed to an under collection for the cost of fuel over the past year. The elevated demand for power resulted in the highest energy usage week on record in the Carolinas.
|
LFGP | Hot Stocks15:35 EDT Ledyard Financial Group increases quarterly dividend 1c to 18c - Ledyard Financial Group announced a 1c increase to its quarterly dividend. The dividend of 18c is payable September 4 to shareholders of record as of August 10.
|
BAYRY NFLX | Hot Stocks15:19 EDT Bayer says Netflix's The Bleeding Edge 'lacks scientific support' - Bayer (BAYRY) released a "Fact Check" of The Bleeding Edge, based on Bayer's review of the film's premiere at the Tribeca Film Festival on April 21. The film, which premieres on Netflix (NFLX) on July 27, devotes significant time to Essure, the only FDA-approved non-incisional form of permanent birth control, and is now the subject of media coverage by The New York Times, CBS News, and others, Bayer said. The maker of Essure stated in part: "As a leader in women's healthcare, Bayer believes strongly that women and their physicians should make reproductive health decisions based on sound science. In contrast, the portrayal of Essure in The Bleeding Edge lacks scientific support, despite the fact that Bayer provided the producers with extensive scientific information on Essure before the completion of the film. The film presents an inaccurate and misleading picture of Essure by relying almost entirely on anecdotes, cherry-picking information to fit a predetermined conclusion, ignoring the full body of scientific evidence that supports the Food and Drug Administration's determination that Essure's benefits outweigh its risks and disregarding the appropriate warnings that accompany the device...Notably, the film's only reference to scientific data regarding Essure is the 2018 Bouillon study published in the Journal of the American Medical Association, which its producers cite out of context and portray in its least favorable light. Taken as a whole, the study actually undermines the central premise of the film's representation of Essure."
|
AEP | Hot Stocks14:02 EDT American Electric cancels Wind Catcher project after Texas PUC denial - American Electric Power announced that it is canceling the Wind Catcher project as a result of the Public Utility Commission of Texas' July 26 decision to deny approval of the project. The project had been approved by the Arkansas Public Service Commission, Louisiana Public Service Commission and Federal Energy Regulatory Commission. A decision was pending at the Oklahoma Corporation Commission. "We are disappointed that we will not be able to move forward with Wind Catcher, which was a great opportunity to provide more clean energy, lower electricity costs and a more diverse energy resource mix for our customers in Arkansas, Louisiana, Oklahoma and Texas. To realize the full benefits of Wind Catcher for customers, timely approvals were required from all jurisdictions so we could complete the project by the end of 2020 and be eligible for 100% of the federal production tax credit...The strategic investments we are making in AEP's regulated businesses will continue to support our 5% to 7% earnings growth rate. We are investing in a cleaner, smarter energy system for our customers and will continue to pursue opportunities to provide the new energy resources and technology solutions that bring value to our customers," said Nicholas K. Akins, AEP chairman, president and CEO.
|
CBS | Hot Stocks13:56 EDT CBS independent directors issue statement regarding The New Yorker report - The statement from the CBS independent directors reads: "All allegations of personal misconduct are to be taken seriously. The Independent Directors of CBS have committed to investigating claims that violate the Company's clear policies in that regard. Upon the conclusion of that investigation, which involves recently reported allegations that go back several decades, the Board will promptly review the findings and take appropriate action. The timing of this report comes in the midst of the Company's very public legal dispute. While that litigation process continues, the CBS management team has the full support of the independent board members. Along with that team, we will continue to focus on creating value for our shareowners."
|
CHTR | Hot Stocks13:52 EDT NY PSC rescinds Charter merger approval - The New York State Public Service Commission announced it has revoked its approval of the 2016 merger agreement between Charter Communications and Time Warner Cable because Charter, doing business as Spectrum, "has - through word and deed - made clear that it has no intention of providing the public benefits upon which the Commission's earlier approval was conditioned." The Commission rejected Charter's "good cause" claims as part of the orders issued today. Consequently, the Commission directed that Charter pay $1M to the State Treasury for missing the June milestone, bringing the total amount of payments ordered by the Commission to $3M, and directed the Commission's counsel to bring an enforcement action in State Supreme Court to seek additional penalties for Charter's past failures and on-going non-compliance. That enforcement action will be filed today in State Supreme Court in Albany.
|
MBVX | Hot Stocks13:21 EDT MabVax Therapeutics announces filing of Delaware petition - MabVax Therapeutics announced that it filed a Verified Petition for Relief Under 8 Del. C. Section 205 in the Court of Chancery of the State of Delaware. The Delaware Petition seeks an order of the Court validating (i) conversions of the company's preferred stock into common stock that occurred between June 30, 2014 and February 12, 2018, and (ii) corporate acts that may not have been approved by the requisite percentage of stockholder voting power during the same time period. The court has not yet set a hearing date with respect to the Delaware Petition. Once a hearing date is fixed, the company said it intends to inform stockholders of that hearing date by issuing a subsequent press release.
|
IZEA | Hot Stocks13:10 EDT Izea receives approval of delisting request from German Stock Exchange - IZEA announced that it has received confirmation from the Borse-Stuttgart Stock Exchange that the company will delist IZEA's stock, traded under the symbol "2IZ" in Germany. The Stuttgart Stock Exchange has formally announced the intent to delist the common stock of IZEA today, with the last day of trading to be September 7, 2018, in accordance with its terms and conditions. The company contacted both the Borse Berlin-Bremen Stock Exchange and the Stuttgart Stock Exchange requesting delisting of any IZEA securities. The BBSE has indicated that IZEA's stock is not listed or traded on their exchange.
|
BHGE | Hot Stocks13:03 EDT Baker Hughes reports U.S. rig count up 2 to 1,048 rigs - Baker Hughes reports that the U.S. rig count is up 2 rigs from last week to 1,048, with oil up 3 to 861, gas rigs down 1 to 186, and miscellaneous rigs unchanged at 1. The U.S. Rig Count is up 90 rigs from last year's count of 958, with oil rigs up 95, gas rigs down 6, and miscellaneous rigs up 1. The U.S. Offshore Rig Count is down 1 rig to 16 and down 8 rigs year-over-year. The Canada Rig Count is up 12 rigs from last week to 223, with oil rigs up 12 to 154 and gas rigs unchanged at 69. The Canada Rig Count is up 3 rigs from last year's count of 220, with oil rigs up 25 and gas rigs down 22.
|
ABT | Hot Stocks13:02 EDT Abbott's FreeStyle Libre 14 day Flash Glucose Monitoring System approved by FDA - Abbott announced that the U.S. Food and Drug Administration has approved the FreeStyle Libre 14 day Flash Glucose Monitoring system, which allows people with diabetes to wear the sensor up to 14 days with high accuracy. This approval makes Abbott's revolutionary continuous glucose monitor the longest lasting self-applied personal glucose sensor available on the market. "At Abbott, we are continuously pushing for new innovations that minimize the daily burden of managing diabetes," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "With the new FreeStyle Libre 14 day system, people with diabetes will now have extended access to their glucose data with a high degree of accuracy, which will improve their experience and help empower them to better manage their condition."
|
CYS TWO | Hot Stocks13:02 EDT CYS Investments stockholders approve merger with Two Harbors - CYS Investments (CYS) announced that at a special meeting its stockholders approved the merger transaction in which an indirect, wholly owned subsidiary of Two Harbors Investment (TWO) will merge with and into CYS, pursuant to the previously announced merger agreement among CYS, merger sub and Two Harbors. At the special meeting, approximately 59.50% of the outstanding shares of CYS common stock were voted, with approximately 96.52% of the votes cast in favor of the CYS merger proposal. The merger is expected to close on July 31, subject to customary closing conditions. CYS common stock is expected to be delisted from trading on the New York Stock Exchange after the close of trading on July 31. Two Harbors common stock will continue to trade on the NYSE under the existing ticker symbol "TWO".
|
ATVI SNE | Hot Stocks13:01 EDT Call of Duty World League Stage 2 Playoffs continue this weekend - Activision Blizzard's (ATVI) Call of Duty World League continues this weekend when the top eight teams from around the world will compete for a $500,000 event prize pool at the CWL Pro League Stage 2 Playoffs, presented by PlayStation 4 (SNE). The Playoff champions become early favorites for the 2018 Call of Duty World League Championship taking place August 15-19. Final placements at the CWL Pro League Stage 2 playoffs will help determine seeding for the 2018 Call of Duty World League Championship.
|
INSY | Hot Stocks12:53 EDT Insys Therapeutics down 7% after announcing CRL for buprenorphine - Insys shares are down 51c, or 7%, to $6.77.
|
INSY | Hot Stocks12:51 EDT Insys Therapeutics announces receipt of CRL from FDA for buprenorphine NDA - Insys Therapeutics announced that it received a Complete Response Letter, or CRL, from the U.S. Food and Drug Administration regarding the company's New Drug Application for a buprenorphine sublingual spray as a treatment for moderate-to-severe acute pain. "Consistent with the outcome of an FDA Advisory Committee meeting in May, the CRL indicates that, although the clinical development program demonstrated all three proposed doses of the product candidate were statistically significantly different than placebo in providing pain relief, some of the data suggested potential safety concerns. Given the attributes of our proprietary buprenorphine formulation for sublingual delivery, we continue to believe that this drug-device combination could bring value to the management of pain and will assess the next steps in the context of the company's overall mission," said Insys.
|
INSY | Hot Stocks12:50 EDT Insys Therapeutics announces receipt of CRL from FDA for buprenorphine NDA
|
EA... | Hot Stocks12:21 EDT Analysts still bullish on EA despite downbeat guidance - Shares of Electronic Arts (EA) are sliding in early afternoon trading after the video game publisher provided guidance for the upcoming quarter and fiscal year in its quarterly report that was below analysts' expectations. Despite the weak guidance, several analysts maintained bullish stances on stock. WHAT'S NEW: After the market close yesterday, EA released results for its fiscal first quarter, reporting Q1 adjusted earnings per share of 15c on net bookings of $749M, which both beat analysts' estimates for 6c and $742.2M, respectively. However, the company said that it expects second quarter EPS of approximately 48c on net bookings of $1.16B, compared to Wall Street expectations of 70c and $1.23B. In addition, EA provided its outlook for the full year, guiding for FY19 EPS of approximately $3.55 and net bookings of approximately $5.55B. Analysts expect EA to report FY19 EPS of $5.02 on net bookings of $5.6B. WHAT'S NOTABLE: Electronic Arts reported Live Services revenue of $610M for the quarter, which is 22% higher than that segment's revenue in the same quarter last year but lower than the $698M figure reported last quarter. Live Services revenue has become particularly relevant in the video game sector, as games like EA's "FIFA Ultimate Team" and Epic's "Fortnite: Battle Royale" continue to generate revenue through in-game purchases. In addition, Piper Jaffray analyst Michael Olson said prior to EA's earnings report that he was looking for Live Services from "FIFA Ultimate Team" amid the World Cup to drive results. Epic Games, the creator of "Fortnite," is 40% owned by Tencent (TCEHY) and is part of Disney's (DIS) Accelerator Program. STREET RESEARCH: Following the earnings report, Wedbush Securities analyst Michael Pachter reiterated an Outperform rating and $158 price target on EA, saying that the company delivered upside to its guidance in the quarter. Pachter noted that "FIFA Ultimate Team" underwhelmed relative to bullish investor expectations, and that Live Services revenue grew far more slowly than in previous quarters. Still, the analyst said he remains bullish about EA's prospects in fiscal 2019, calling concerns over continued Live Services weakness and a crowded holiday schedule "unwarranted." Meanwhile, KeyBanc analyst Evan Wingren backed an Overweight rating and $168 price target on the stock, saying he recommends buying EA on the weakness, as Q1 results were "mixed." The analyst added that he continues to see potential upside relative to consensus estimates. In addition, UBS analyst Eric Sheridan maintained a Buy rating and $176 price target on EA, saying that "a little noise" from Q1 on Live Services growth doesn't impact the long term narrative. Sheridan added that the shares remain compelling despite the stock's recent move. PRICE ACTION: In afternoon trading, Electronic Arts shares are down 6.22% to $133.08.
|
CBS | Hot Stocks12:15 EDT CBS to CNBC: 'All allegations of personal misconduct are to be taken seriously' - Commenting on the allegations against CEO Les Moonves, the CBS board tells CNBC that "All allegations of personal misconduct are to be taken seriously. The Independent Directors of CBS have committed to investigating claims that violate the company's clear policies in that regard." The board also says the timing of the report "comes in the midst of the company's very public legal dispute. While that litigation process continues, the CBS management team has the full support of the independent board members." Reference Link
|
IDRA | Hot Stocks12:02 EDT Idera announces one-for-eight reverse stock split - Idera Pharmaceuticals announced that its board has approved a one-for-eight reverse stock split of its common stock that will be effective at 5:00 pm ET. Beginning with the opening of trading on July 30, the company's common stock will trade on the Nasdaq Capital Market on a split-adjusted basis. The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 217.4M to approximately 27.2M. Concurrently, the authorized number of shares of common stock will be set at 70M.
|
TWO CYS | Hot Stocks12:01 EDT Two Harbors investors approve merger with CYS Investments - Two Harbors Investment Corp. (TWO) announced that at the special meeting of stockholders held today its stockholders approved the issuance of the company's common stock pursuant to the terms of the previously announced merger agreement with CYS Investments (CYS). The merger is expected to close on July 31, 2018, subject to customary closing conditions. As a result of the merger, among other things, each share of CYS common stock outstanding at the effective time of the merger will be converted into the right to receive from Two Harbors (i) 0.4680 newly issued shares of Two Harbors common stock and (ii) cash consideration of $0.0965 per share. CYS common stock is expected to be delisted from trading on the New York Stock Exchange after the close of trading on July 31, 2018. Two Harbors common stock will continue to trade on the NYSE under the existing ticker symbol "TWO".
|
ENVA | Hot Stocks12:00 EDT Enova International falls -13.9% - Enova International is down -13.9%, or -$5.05 to $31.35.
|
TWTR | Hot Stocks12:00 EDT Twitter falls -18.5% - Twitter is down -18.5%, or -$7.95 to $34.99.
|
AMID | Hot Stocks12:00 EDT American Midstream Partners falls -42.9% - American Midstream Partners is down -42.9%, or -$4.96 to $6.59.
|
AUY | Hot Stocks12:00 EDT Yamana Gold rises 12.7% - Yamana Gold is up 12.7%, or 35c to $3.11.
|
HF | Hot Stocks12:00 EDT HFF Inc. rises 13.3% - HFF Inc. is up 13.3%, or $5.19 to $44.13.
|
INT | Hot Stocks12:00 EDT World Fuel Services rises 19.4% - World Fuel Services is up 19.4%, or $4.33 to $26.69.
|
HMNY | Hot Stocks11:51 EDT Helios and Matheson plummets after disclosing $5M loan to fix MoviePass outage - MoivePass stopped working on the evening of July 26 because it ran out of money. Helios and Matheson (HMNY), who owns MoviPass, had to borrow $5M to turn the service back on. WHAT'S NEW: Helios and Matheson disclosed in a regulatory filing that on July 27, the company issued a demand note in the amount of $6.2M, which includes $5M in cash. The $5M cash proceeds received from the demand note will be used by the company to pay the company's merchant and fulfillment processors. If the company is unable to make required payments to its merchant and fulfillment processors, the merchant and fulfillment processors may cease processing payments for MoviePass, which would cause a MoviePass service interruption. Such a service interruption occurred on July 26. Such service interruptions could have a material adverse effect on MoviePass' ability to retain its subscribers. This would have an adverse effect on the company's financial position and results of operations. WHAT'S NOTABLE: Helios and Matheson announced a 1-for-250 share reverse stock split on July 24. The reverse stock split was approved by shareholders on July 23 and the common stock began trading on a split-adjusted basis on Wednesday, July 25. The reason for the stock split was that the company was at risk of being delisted from the Nasdaq if it continued to trade below $1 with a market cap under $50M. PRICE ACTION: Shares of Helios and Matheson plummeted 53% following the disclosure. Shares are trading at $3.21 at mid-day after opening at $6.83.
|
CMI | Hot Stocks11:49 EDT Cummins announces settlement agreement with JM Turbo Technology - Cummins announced a settlement agreement has been reached with JM Turbo Technology Corporation precluding the manufacture or sale of products that infringe Cummins patents. As part of the settlement agreement, JM Turbo Technology acknowledged it illegally marketed and sold turbochargers protected by Cummins' patents and other intellectual property rights registered in multiple countries. In addition, Cummins patents were infringed, valid and enforceable. Conditions of the settlement include JM Turbo Technology's agreement to stop all manufacturing, importation, exportation, advertising and/or sale of all infringing products. The settlement also calls for JM Turbo Technology to destroy all existing inventory of the infringing products, Cummins stated.
|
JPM SSNLF | Hot Stocks11:48 EDT Chase Pay, Samsung Pay join forces - Starting today, Chase Pay (JPM) customers with compatible flagship Samsung (SSNLF) Galaxy smartphones now have the option to link Chase Pay to Samsung Pay. The companies said, "This means that customers will now be able to use Samsung Pay's Magnetic Secure Transmission technology, along with NFC, to pay with the Chase Pay app at millions of merchants in the United States by simply tapping the payment terminal. Bringing together the two wallets offers Chase cardholders more ways to pay with their mobile phones and at more places. Samsung Pay is accepted at nearly all payment terminals, making it the most widely accepted mobile payment product in the United States."
|
BTC... | Hot Stocks11:41 EDT The Intersection: Crypto and Wall Street This Week - As bitcoin, ethereum and other cryptocurrencies get increasing attention from investors, Wall Street and its traditional banks continue to adjust to the shift. Catch up on this week's top stories highlighting the intersection of these old guard and new school areas of finance with this recap compiled by The Fly. 1. BITCOIN ETF REJECTED BY SEC: The U.S. Securities and Exchange Commission stood by a decision blocking a bitcoin exchange-traded fund proposed by Cameron and Tyler Winklevoss, twins who founded crypto exchange Gemini Trust, Reuters reported Friday. "Regulated bitcoin-related markets are in the early stages of their development," the SEC said, saying that it "cannot...conclude that bitcoin markets are uniquely resistant to manipulation." The vote to block the ETF was 3-1, with Republican commissioner Hester Peirce dissenting, saying she believed the product met the legal standard. 2. RIOT ANNOUNCES MINING POOL PRIVATE BETA: On Monday, Riot Blockchain (RIOT) announced the beta development of its own private Bitcoin Mining Pool. Mining pools are groups of miners that work as a team and contribute their hashing power to solving computations that secure the blockchain. On Wednesday, H.C. Wainwright analyst Kevin Dede reiterated a Buy rating and a $10 price target on the name citing bitcoin's recent surge. The analyst said Riot continues to "bulldoze" mining capabilities on multiple fronts and the mining pool could assist in democratizing bitcoin mining by offsetting major miners' adverse intentions. In addition, as the pool size increases, the probability of securing block rewards should also increase serving as a boost to Riot's mining returns, Dede said. 3. GOOGLE BANS CRYPTO MINING ON PLAY STORE: Google (GOOG, GOOGL) will no longer allow cryptocurrency miners on its Play Store, Android Police reported Thursday. The move comes as the company updates its Play Store developer policies and after crypto mining extensions were banned from the Chrome Web Store earlier in 2018. 4. SSC, CVCRI FORM PARTNERSHIP: On Monday, Seven Stars Cloud Group (SSC) announced that the company has entered into an exclusive agreement with the China Venture Capital Research Institute and its subsidiaries. As a result, SSC will be able to provide fractionalization and securitization in China to create new fixed income classes that can be traded on government designated exchanges, regulated products and assets traded on regulated exchanges outside of China and tokenization of these asset classes, including already issued Real Estate Investment Trusts and Asset-backed Securities. 5. CRYPTO FIRM TAKES $134M LOSS: Crypto merchant bank Galaxy Digital, which was founded by ex-hedge fund manager Mike Novogratz, took a $134M hit in the first quarter amid bitcoin's drop in value, CNBC reported Thursday. The firm reported a net loss of $103.3M on trading, with $13.5M on digital assets and another $85.5M of unrealized losses on those assets. Novogratz said he still has "complete confidence" in the team's ability to drive growth and that Galaxy is "strategically positioned to help further institutionalize the digital assets and blockchain industry." CRYPTO STOCK PLAYS: Cryptocurrency revenues have been pointed to as reasons to be bullish on Advanced Micro Devices (AMD) and Nvidia (NVDA) in select research. Overstock (OSTK), DPW Holdings (DPW), Kodak (KODK), Seven Stars Cloud, Riot Blockchain, Pareteum (TEUM) and Social Reality (SRAX) are other stocks that have been touted, or promoted themselves, as a way to play the crypto theme. PRICE ACTION: As of time of writing, bitcoin rose about 8.4% this week to $8,135 in U.S. dollars, according to CoinDesk. WANT BITCOIN NEWS ALERTS?: To receive alerts on stories relating to bitcoin and other cryptocurrencies, Fly subscribers can enter "Bitcoin" into the "Add symbols" box of their portfolios.
|
CVX | Hot Stocks11:35 EDT Chevron says will consider deepwater investments in 2019-2021 plan
|
BYD | Hot Stocks11:29 EDT Boyd Gaming named new short idea at Hedgeye - Boyd Gaming has been named a new short idea at Hedgeye, according to contacts.
|
VIA... | Hot Stocks11:27 EDT Box Office Battle: 'Mission: Impossible - Fallout' cruises into theaters - Opening this weekend is Viacom (VIA, VIAB) subsidiary Paramount's action film "Mission: Impossible - Fallout," the sixth film in the series starring Tom Cruise as super spy Ethan Hunt. The movie already earned $6M in Thursday night previews, and is expected to open domestically in the $65M-$75M range. Despite this strong opening, Imperial Capital analyst David Miller said in a research note that the film will not be a catalyst for Viacom despite its profitability, as it is already built into the stock. Miller maintained an Underperform rating on Viacom shares. Also opening this weekend is AT&T (T) subsidiary Warner Bros animated "Teen Titans Go! To the Movies," which is expected to gross $17M-$18M this weekend, competing with Comcast (CMCSA, CMCSK) subsidiary Universal's "Mamma Mia! Here We Go Again" for second place at this weekend's box office. Also in its second weekend at theaters is Sony's (SNE) action thriller "The Equalizer 2," starring Denzel Washington, which is expected to bring in an additional $16M-$17M after winning last weekend's box office. Publicly traded companies in the space include 21st Century Fox (FOX, FOXA), Disney (DIS), and Lionsgate (LGF.A, LGF.B).
|
CVX | Hot Stocks11:26 EDT Chevron says being 'conservative' with share buyback plans
|
CVX | Hot Stocks11:26 EDT Chevron intends buyback to be 'sustainable' in the future
|
JBLU | Hot Stocks11:21 EDT JetBlue reports pilots approve four-year agreement - JetBlue with its pilots, represented by the Air Line Pilots Association, Int'l, announced the ratification of a four-year contract. Of the 98% of pilots who voted, 74% cast ballots voted in favor of the agreement. The contractual terms, including market competitive pay rates, per diems and 401(k) provisions, will be effective August 1, 2018.
|
GWR | Hot Stocks11:14 EDT Genesee & Wyoming evaluating a number of acquisitions, investment opportunities - Says North American revenue continued to strengthen in Q2. Says evaluating a number of acquisitions and investment opportunities in multiple geographies. Says Australia performance continues to be on plan. Says UK locomotive fleet rationalization partially deferred into 2H18 given strengthening commercial demand for bulk commodity shipments. Says can either incur $23M of equipment charges in 2H18 yielding $8M of annual savings or new business can be contracted for higher profit using excess equipment. Comments taken from Q2 earnings conference call.
|
CVX | Hot Stocks11:11 EDT Chevron sees FY worldwide net oil & gas production in upper half of guidance - Cites 2H growth drivers, including Wheatstone Train 2 ramp-up, shale & tight growth, other MCP ramp-up. Says "on track" to deliver 2018 cash generation in line with guidance, financial priorities "unchanged." Says capital and exploratory expenditures at about $9B mid-year. Says will start repurchases in Q3. Says aims to "modestly" reduce debt levels. Comments taken from the Q2 earnings conference call. Chevron is up about 1% in morning trading to $125.17.
|
FOXA... | Hot Stocks10:54 EDT 21st Century Fox and Disney stockholders approve acquisition agreement - Twenty-First Century Fox (FOXA) and Disney (DIS) announced that, at separate special meetings today, stockholders of the two companies approved all proposals related to Disney's acquisition of 21st Century Fox. The proposals included the adoption by 21st Century Fox stockholders of the merger agreement with Disney and the distribution merger agreement for the spin-off of new "Fox." Disney stockholders approved the issuance of new common stock that will be distributed to 21st Century Fox stockholders as part of the acquisition. Under the Disney merger agreement, 21st Century Fox stockholders may elect to receive $38 per share in either cash or shares of New Disney, a new holding company that will become the parent of both Disney and 21st Century Fox. As a result, current 21st Century Fox stockholders will own a 17-20% stake in "New Disney" on a pro forma basis. Last month, the U.S. Department of Justice entered into a consent decree with Disney and 21st Century Fox that allows the transaction to proceed, while requiring the sale of the Fox Sports Regional Networks. Completion of the transaction is subject to a number of non-U.S. merger and other regulatory reviews, and other customary closing conditions.
|
JBLU | Hot Stocks10:54 EDT JetBlue pilots vote to ratify tentative agreement - JetBlue pilots, represented by the Air Line Pilots Association, Int'l, or ALPA, have ratified the tentative agreement, which now becomes the pilot group's first collective bargaining agreement with the company. With 98 percent of eligible pilots participating, 74 percent voted to ratify the tentative agreement. The agreement provides significant increases in pay, improvements to retirement, and enhanced working conditions. The pilots have been in negotiations with the company for more than three years after bringing ALPA on to the property. In May 2018, an agreement in principle was reached with the company, which was then expanded into full contract language in June.
|
DXCM ABT | Hot Stocks10:27 EDT DexCom drops after FDA expands approval of Abbott's Libre - Shares of DexCom (DXCM) are falling after Piper Jaffray analyst JP McKim highlighted the FDA's approval letter of Abbott's (ABT) FreeStyle Libre for 14-day wear and a 1-hour warm-up. This compares to the initial approval at 10-day wear and 12-hour warm-up for the glucose monitoring system, McKim told investors last night in a research note. DexCom shares are down 8%, or $8.59, to $93.40 in morning trading. The analyst notes, however, that even with the 1-hour warm-up, it appears Libre still has a non-adjunctive claim. It is unclear at this time what Abbott will do on pricing as currently, patients get there sensors for around $75, McKim writes. If Abbott keeps the same per sensor price of $25 and drops the monthly price to $50, that would make the price gap even greater relative to DexCom, he adds. The analyst views the news as more of a negative headline for DexCom than an impact estimates. He points out that DexCom is working on 14-day indication and 1-hour warm-up as well.
|
VRTX | Hot Stocks10:26 EDT CHMP adopts positive opinion on Symkevi - The EMA announced earlier that the Committee for Medicinal Products for Human Use, or CHMP, adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Symkevi, intended for the combination treatment of patients with cystic fibrosis aged 12 years and older. The applicant for this medicinal product is Vertex Pharmaceuticals. Reference Link
|
ABT DXCM | Hot Stocks10:20 EDT Abbott's FreeStyle Libre granted FDA approval for expanded indications - The Center for Devices and Radiological Health of the Food and Drug Administration has completed its review of Abbott's (ABT) premarket approval application supplement and approved the supplement for the FreeStyle Libre 14 Day Flash Glucose Monitoring System for expanding the indications to extend the sensor wear period to 14 days, and reduce the sensor warm up time to 1 hour, according to a letter dated July 23 that was posted to the Administration's website. The expanded approval for the Abbott system may be having a hand in the weakness being seen this morning in shares of DexCom (DXCM). Reference Link
|
HIG... | Hot Stocks10:16 EDT Hartford says talc 'specifically excluded' from excess policy with Berkshire
|
SSP | Hot Stocks10:07 EDT E.W. Scripps to sell Milwaukee radio stations to Good Karma Brands for $16M - The E.W. Scripps Company has reached an agreement to sell its two radio stations in Milwaukee, Wisconsin, to Good Karma Brands for $16M. Good Karma Brands is purchasing WTMJ (620 AM and 103.3 FM) and WKTI (94.5 FM). The transaction is expected to close in the fourth quarter. The sale is the second in what Scripps expects to be a series of radio sale transactions. In June, it announced the sale of five radio stations in Tulsa, Oklahoma, to Tulsa-based Griffin Communications. The company announced in January its intent to sell its portfolio of 34 radio stations in eight markets.
|
SSP | Hot Stocks10:05 EDT E.W. Scripps sell Milwaukee radio stations to Good Karma Brands for $16M - The E.W. Scripps Company has reached an agreement to sell its two radio stations in Milwaukee, Wisconsin, to Good Karma Brands for $16M. Good Karma Brands is purchasing WTMJ (620 AM and 103.3 FM) and WKTI (94.5 FM). The transaction is expected to close in the fourth quarter. The sale is the second in what Scripps expects to be a series of radio sale transactions. In June, it announced the sale of five radio stations in Tulsa, Oklahoma, to Tulsa-based Griffin Communications. The company announced in January its intent to sell its portfolio of 34 radio stations in eight markets.
|
DYSL | Hot Stocks10:01 EDT Dynasil Corporation of America unit awarded four Phase I grants - Dynasil Corporation of America announced its Radiation Monitoring Devices subsidiary has received four Phase I grants totaling $600,000 under the U.S. Department of Energy's Small Business Innovation Research and Small Business Technology Transfer Programs.
|
SAM | Hot Stocks10:00 EDT Boston Beer falls -14.3% - Boston Beer is down -14.3%, or -$44.48 to $267.23.
|
TWTR | Hot Stocks10:00 EDT Twitter falls -15.6% - Twitter is down -15.6%, or -$6.68 to $36.26.
|
AMID | Hot Stocks10:00 EDT American Midstream Partners falls -39.4% - American Midstream Partners is down -39.4%, or -$4.55 to $7.00.
|
CHK | Hot Stocks10:00 EDT Chesapeake rises 7.8% - Chesapeake is up 7.8%, or 34c to $4.75.
|
INT | Hot Stocks10:00 EDT World Fuel Services rises 14.3% - World Fuel Services is up 14.3%, or $3.19 to $25.55.
|
FIX | Hot Stocks10:00 EDT Comfort Systems USA rises 19.1% - Comfort Systems USA is up 19.1%, or $9.40 to $58.50.
|
HIG | Hot Stocks09:59 EDT Hartford Financial sees headwinds on the pricing side in workers' comp in 2H - Comment taken from the Q2 earnings conference call.
|
FIX | Hot Stocks09:47 EDT Comfort Systems USA rises 6.7% - Comfort Systems USA is up 6.7%, or $3.30 to $52.40.
|
INT | Hot Stocks09:47 EDT World Fuel Services rises 8.2% - World Fuel Services is up 8.2%, or $1.83 to $24.19.
|
CHK | Hot Stocks09:47 EDT Chesapeake rises 12.5% - Chesapeake is up 12.5%, or 55c to $4.95.
|
CHRS | Hot Stocks09:41 EDT Coherus Biosciences announces positive CHMP opinion for UDENYCA - Coherus BioSciences announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion for the marketing authorization of UDENYCA, a Neulasta biosimilar candidate. "UDENYCA has the opportunity to become one of the first pegfilgrastim biosimilars to gain Marketing Authorization in Europe. The positive opinion issued by the CHMP today is a significant milestone for Coherus, as it validates both our UDENYCA biosimilarity package as well as our development platform as a whole. We believe UDENYCA will represent an important option for patients, providers and payers seeking alternatives for the treatment and prevention of febrile neutropenia due to cytotoxic chemotherapy in Europe," the company stated.
|
MNKD | Hot Stocks09:39 EDT MannKind, Tanner Pharma enter ex-U.S. distribution pact for Afrezza - MannKind announced a distribution agreement for Afrezza with Tanner Pharma Group. The agreement names Tanner as a distributor of Afrezza outside of the United States in regions the product is not yet registered. Afrezza Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.
|
JNJ | Hot Stocks09:34 EDT Johnson & Johnson announces CHMP recommendation for Darzalex - Janssen Pharmaceutical of Johnson & Johnson announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has recommended broadening the existing marketing authorisation for Darzalex for use as frontline therapy. The recommendation is for the use of daratumumab in combination with bortezomib, melphalan and prednisone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant, or ASCT. The CHMP's recommendation is based on results from the randomised, open-label, multicentre Phase 3 ALCYONE study. A final decision regarding the approval of daratumumab for newly diagnosed patients is expected from the European Commission in the coming months.
|
SBUX | Hot Stocks09:32 EDT Starbucks 'seeing a bit more competition' in China, CEO says - Starbucks CEO Kevin Johnson is speaking on CNBC.
|
CHRS AMGN | Hot Stocks09:30 EDT EMA grants positive CHMP opinion on two biosimilars of Amgen's Neulasta - The Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Udenyca, intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. The applicant for this medicinal product is ERA Consulting GmbH. The CHMP also adopted a positive opinion recommending the granting of a marketing authorization for the medicinal product Pelgraz, which is also intended to reduce the duration of neutropenia and the incidence of febrile neutropenia due to chemotherapy. Udenyca and Pelgraz are biosimilar medicinal products "highly similar" to the reference product Neulasta, the EMA said. Analysts at Citi have said "Udenyca" is registered under Coherus Biosciences (CHRS) and it seems to them that a third party filed the application on Coherus' behalf. Neulasta is marketed by Amgen (AMGN). Reference Link
|
SBUX | Hot Stocks09:30 EDT Starbucks CEO says 'challenges' in U.S. business is around afternoon - Starbucks CEO Kevin Johnson is speaking on CNBC.
|
SBUX | Hot Stocks09:29 EDT Starbucks CEO says core U.S. business in morning is 'healthy and strong' - Starbucks CEO Kevin Johnson is speaking on CNBC.
|
SYF | Hot Stocks09:26 EDT Synchrony: 'we feel really good' about ability to execute either Walmart options - Synchrony (SYF) management said they feel really good about their ability to execute either option considered with what to do with the Walmart (WMT) portfolio. Management noted that either option is accretive to EPS relative to renewal terms.
|
AMZN... | Hot Stocks09:16 EDT Fly Intel: Pre-market Movers - UP AFTER EARNINGS: Amazon (AMZN), up 4%... Chipotle (CMG), up 6%... Atlassian (TEAM), up 16%... Expedia (EXPE), up 10%. ALSO HIGHER: Chesapeake Energy (CHK), up 14% after announcing an agreement to sell its interests in the Utica Shale operating area located in Ohio for approximately $2B... AMD (AMD), up 4% after Intel (INTC) provided commentary that has analysts voicing concerns around the company's ramp of its 10nm process. DOWN AFTER EARNINGS: Twitter (TWTR), down 13%... Intel, down 6%... Exxon Mobil (XOM), down 4%... Chevron (CVX), down 1.5%... First Solar (FSLR), down 5%... Magellan Health (MGLN), down 11.5%... Imperva (IMPV), down 21.5%... Electronic Arts (EA), down 3%.
|
ABBV | Hot Stocks09:13 EDT AbbVie expects performance in 2H18 to continue to be 'robust' - Says delivered "strong" topline results in the quarter driven by growth from several assets across the portfolio, including Humira, Imbruvica and. Mavyret. Expects performance in the 2H18 to continue to be "robust". Says expects Imbruvica momentum to continue. Says Mavyret has achieved market-leading position in the U.S. Says continues to make "excellent progress" with late-stage R&D products. Says Orilissa represents a significant long-term opportunity. Says remains on track to submit regulatory application for upadacitinib later this year. Says submitted BLA and MAA for risankizumab. Expects further diversification going forward. Expects to be "extremely well-positioned" by 2020 with diversified assets. Says confident in ability to continue to drive strong growth. Comments taken from Q2 earnings conference call.
|
MYL | Hot Stocks09:12 EDT Mylan and Fujifilm announce EMA adopted positive opinion of Hulio - Mylan and Fujifilm Kyowa Kirin Biologics announced that the European Medicines Agency's Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion for the Marketing Authorization Application of Hulio, the companies' biosimilar to Humira, or adalimumab, for all indications. The decision of the European Commission on the approval is expected in October.
|
AMD INTC | Hot Stocks09:12 EDT AMD rises after Intel signals difficulty with move to 10nm - Shares of AMD (AMD) are rising in pre-market trading after Intel (INTC) provided commentary that has analysts voicing concerns around the company's ramp of its 10nm process. Delays in Intel's 10nm product ramp and process node transitions may translate to a disadvantage to AMD in servers in the second half of 2019, Jefferies analyst Mark Lipacis tells investors. In pre-market trading, shares of AMD are up 4% to $19.15, while Intel is down 6% to $49 per share.
|
FDS | Hot Stocks09:10 EDT FactSet appoints Helen Shan as CFO - FactSet announced that Helen Shan will join as CFO in September. She will join FactSet following her position at Marsh and McLennan Companies, where she was CFO for Mercer.
|
AZN | Hot Stocks09:08 EDT AstraZeneca reports positive EU CHMP opinion for Imfinzi in NSCLC - AstraZeneca and MedImmune, its global biologics research and development arm, announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion, recommending a marketing authorization of Imfinzi for the treatment of locally-advanced, unresectable non-small cell lung cancer in adults whose tumors express PD-L1 on greater than or equal to1% of tumor cells and whose disease has not progressed following platinum-based chemotherapy and radiation therapy. The recommendation is based on the progression-free survival and overall survival primary endpoints of the Phase 3 PACIFIC trial, and post-hoc subgroup analyses by PD-L1 expression requested by the CHMP.
|
SMLP XOM | Hot Stocks09:05 EDT Summit Midstream executes agreement with Exxon Mobil subsidiary - Summit Midstream Partners (SMLP) announced that it has executed a precedent agreement with XTO Energy, a wholly owned subsidiary of Exxon Mobil (XOM), and one of the largest leaseholders and most active producers in the northern Delaware Basin, to become a Foundation Shipper on SMLP's Double E Pipeline project. XTO has committed to firm transportation capacity on Double E under a 10-year take-or-pay agreement which increases to 500,000 dekatherms per day, or dth/d. SMLP and ExxonMobil have also executed an equity option agreement, which provides ExxonMobil or an affiliate the right to become an equity partner in Double E.
|
NVS | Hot Stocks08:58 EDT Sandoz receives European Commission approval for biosimilar Hyrimoz - Sandoz, a Novartis division, announced that the European Commission granted marketing authorization to biosimilar Hyrimoz for use in all indications of the reference medicine, including rheumatoid arthritis, plaque psoriasis, Crohn's disease, uveitis and ulcerative colitis. The approval was based on a comprehensive data package comprising analytical, preclinical and clinical research demonstrating that Hyrimoz matches the reference biologic in terms of safety, efficacy and technical quality. A randomized, double-blind, three-arm, parallel study confirmed the pharmacokinetics, immunogenicity and safety of Hyrimoz. The study met the primary endpoint, demonstrating bioequivalence for all primary pharmacokinetic parameters. A Phase III confirmatory safety and efficacy study demonstrated therapeutic equivalence in the sensitive indication of patients with moderate to severe chronic plaque-type psoriasis, with a similar safety and immunogenicity profile to the reference biologic. No meaningful clinical differences were observed.
|
TWTR | Hot Stocks08:48 EDT Twitter says ad engagements up 81% in Q2 - Says sees "lots of ways" to grow revenue in excess of audience near term.
|
TTPH | Hot Stocks08:41 EDT Tetraphase receives positive CHMP opinion for Xerava as treatment for cIAI - Tetraphase Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending Xerava for approval as a treatment for adult patients with complicated intra-abdominal infections. The CHMP's opinion will be reviewed by the European Commission which is expected to make a final decision within three months. If approved by the EC, marketing authorization for Xerava will be granted in all 28 countries of the European Union, Norway, Iceland and Liechtenstein.The CHMP opinion is based on a comprehensive data package from IGNITE1 and IGNITE4, which were part of the Company's phase 3 Investigating Gram-negative Infections Treated with Eravacycline program. In IGNITE1, twice-daily intravenous Xerava met the primary endpoint, demonstrating non-inferiority in clinical cure versus IV ertapenem in 536 patients using a 10% non-inferiority margin. In IGNITE4, a second phase 3 clinical trial in patients with cIAI, twice-daily IV Xerava met the primary endpoint, demonstrating non-inferiority in clinical cure versus IV meropenem in 500 patients using a 12.5% non-inferiority margin. In both IGNITE1 and IGNITE4, Xerava was well-tolerated and achieved high cure rates in patients with Gram-negative pathogens, including resistant isolates. The Company is also using the results from IGNITE1 and IGNITE4 to support a NDA for Xerava in cIAI with the FDA
|
SYF WMT | Hot Stocks08:41 EDT Synchrony says did not reach terms with Walmart that 'made sense' for company - Synchrony management said they did not reach terms with Walmart (WMT) that made economic sense for the company and shareholders. Comments made during Q2 earnings conference call.
|
ARTX | Hot Stocks08:39 EDT Arotech's FAAC wins award valued at $1.9M to support Taiwan Training Range - FAAC Incorporated, a subsidiary of Arotech Corporation's Training and Simulation Division, announced that it has received an award to continue software support and improvement efforts for the Taiwan Training Range. The contract is valued at $1.9M with a period of performance of three years.
|
CQP | Hot Stocks08:38 EDT Cheniere Energy Partners increases quarterly distribution to 56c per unit - Cheniere Energy Partners declared a cash distribution per common and subordinated unit of 56c, or $2.24 annualized, to unitholders of record as of August 6 and the related distribution to its general partner. All of these distributions are payable on August 14.
|
PTLA | Hot Stocks08:37 EDT Portola Pharmaceuticals says CHMP maintains negative opinion on betrixaban - Portola Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a final recommendation on betrixaban for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness with risk factors for VTE, including VTE-related death. The CHMP maintained its negative opinion following a re-examination procedure requested by the Company. The CHMP's position is that betrixaban addresses an unmet medical need and showed a clinically relevant rate of prevention of thrombotic events in patients treated with betrixaban compared to those treated with enoxaparin. However, the committee did not consider the overall risk-benefit profile sufficiently robust when considering non-major bleeding in addition to major bleeding. Portola will continue working with regulatory authorities in countries outside the European Union to potentially bring this important new treatment option to patients as quickly as possible. The Marketing Authorization Application for betrixaban included data from Portola's pivotal Phase 3 APEX Study, which enrolled 7,513 patients at more than 450 clinical sites worldwide. The APEX study evaluated oral betrixaban from hospital admission to home compared with injectable enoxaparin for 6 to 14 days followed by placebo in assessing the prevention of VTE in high-risk acutely ill medical patients. Betrixaban was approved by the U.S. Food and Drug Administration in June 2017 under the trade name Bevyxxa.
|
NEE | Hot Stocks08:37 EDT NextEra Energy affiliates shorten term of PPA for output from DAEC - NextEra Energy Resources through its affiliates NextEra Energy Resources and Alliant Energy's Iowa energy company have agreed to shorten the term of their existing power purchase agreement, or PPA, for the output from the Duane Arnold Energy Center, or DAEC, by five years in exchange for a buyout payment. The companies' new agreements also include new repowered wind PPAs. These transactions will save Alliant Energy's Iowa customers nearly $300M in energy costs, on a net present value basis, over 21 years. Assuming all requisite approvals are received, the DAEC is expected to cease commercial operations in late 2020.
|
GLP | Hot Stocks08:36 EDT Global Partners increases Q2 distribution 2.7% to 47.5c per unit - Global Partners announced that the board of its general partner, Global GP has declared a quarterly cash distribution of 47.5c per unit, or $1.90 per unit on an annualized basis, on all of its outstanding common units for the period from April 1 to June 30. The distribution will be paid August 14 to unitholders of record as of the close of business on August 9. The distribution to be paid in August represents an increase of 2.7%.
|
TWTR | Hot Stocks08:35 EDT Twitter says 'excited about where we are with video'
|
HWC | Hot Stocks08:35 EDT Hancock Whitney raises quarterly dividend 12.5% to 27c per share - Hancock Whitney Corporation announced that at its July meeting, the company's board of directors approved a regular third quarter 2018 common stock cash dividend of 27c per common share. This is an increase of 3c per common share, or 12.5%, in its quarterly dividend. The third quarter dividend is payable September 14, 2018 to shareholders of record as of September 5, 2018.
|
ARRY | Hot Stocks08:35 EDT Array BioPharma announces positive opinion from EMA for Braftovi combination - Array BioPharma announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, adopted a positive opinion recommending approval of BRAFTOVI in combination with MEKTOVI for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union, or EU. The final EC decision, expected by the end of September.
|
CVX | Hot Stocks08:35 EDT Chevron sees share repurchases of $3B per year - "Second quarter earnings were up significantly from a year ago," said Chairman and CEO Michael Wirth. "Results in 2018 benefited from higher crude oil prices, strong operations and higher production. Our cash flow continues to improve with higher upstream margins and volumes, combined with disciplined spending," Wirth added. "This enables us to initiate share repurchases, which are expected to be $3B per year based on our current outlook."
|
CVX | Hot Stocks08:34 EDT Chevron reports Q2 worldwide net oil-equivalent production 2.83M barrels per day - Worldwide net oil-equivalent production was 2.83 million barrels per day in second quarter 2018, compared with 2.78 million barrels per day from a year ago. Growth from project start-ups and ramp-ups was partially offset by asset sales and production entitlement effects. U.S. upstream operations earned $838 million in second quarter 2018, compared with a loss of $102 million from a year earlier. The improvement reflected higher realizations, lower impairment charges and higher crude oil production, partially offset by lower gains on asset sales. Net oil-equivalent production of 739,000 barrels per day in second quarter 2018 was up 38,000 barrels per day from a year earlier. Production increases from shale and tight properties in the Permian Basin in Texas and New Mexico were partially offset by the impact of asset sales of 54,000 barrels per day. The net liquids component of oil-equivalent production in second quarter 2018 increased 8 percent to 575,000 barrels per day, while net natural gas production decreased 5 percent to 980 million cubic feet per day. International upstream operations earned $2.46 billion in second quarter 2018, compared with $955 million a year ago. Net oil-equivalent production of 2.09 million barrels per day in second quarter 2018 was up 8,000 barrels per day from a year earlier. U.S. downstream operations earned $657 million in second quarter 2018, compared with earnings of $634 million a year earlier. Refinery crude oil input in second quarter 2018 decreased 8 percent to 856,000 barrels per day from the year-ago period, primarily due to planned turnaround activity. International downstream operations earned $181 million in second quarter 2018, compared with $561 million a year earlier. Refinery crude oil input of 739,000 barrels per day in second quarter 2018 increased 13,000 barrels per day from the year-ago period, mainly due to the absence of the 2017 crude unit maintenance at the Star Petroleum Refining Company in Thailand and GS Caltex in South Korea, partially offset by the sale of the company's Canadian refining asset in third quarter 2017.
|
ALOT | Hot Stocks08:33 EDT AstroNova secures commitments for ToughWriter printers - AstroNova announced that it has secured multiple commitments for its flagship ToughWriter series of flight deck printers following the Farnborough International Airshow. The show is one of the world's largest aviation events for the aerospace and defense industry. "We received commitments from a number of major airlines that will be installing our narrow format ToughWriter(R) 640 and full format ToughWriter(R) 5 flight deck printers on the new Boeing 737 MAX airplanes ordered at the show," said AstroNova President and CEO Greg Woods. "These contracts speak to the exceptional quality and performance of our products and solidify our position on this next-generation aircraft."
|
TNXP | Hot Stocks08:30 EDT Tonix Pharmaceuticals trading resumes
|
NVS | Hot Stocks08:29 EDT Novartis says CHMP adopts positive opinion for combination Tafinlar + Mekinist - Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar in combination with Mekinist for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection. The CHMP recommendation is based on findings from the COMBI-AD study, which was published in The New England Journal of Medicine. Patients who have been diagnosed with stage III melanoma are at a higher risk of recurrence after surgical resection. The COMBI-AD study found a statistically significant 53% reduction in the risk of recurrence or death in patients treated with the BRAF and MEK inhibitor combination therapy after surgical resection versus placebo.
|
TWTR | Hot Stocks08:28 EDT Twitter says FY18 margin improvement weighted towards first half
|
ABCB | Hot Stocks08:18 EDT Ameris Bancorp sees normalized ROTCE of 16%-18% for 2018 - Regarding M&A opportunities, the company notes that it is focused on organizations that have diversified loan portfolios and REAL deposit franchises and that it is not looking at deals that dilute TBV or that require "exhaustive" strategies to realize meaningful economics. Comments from Q2 earnings presentation slides.
|
TWTR | Hot Stocks08:12 EDT Twitter says 'pleased' with international results - Says international now accounts for more than 50% of revenue. Expects international to grow faster than U.S. Comments from Q2 earnings conference call.
|
ZAYO | Hot Stocks08:11 EDT Zayo Group expands elationship with a global cloud provider in Q2 - Zayo Group Holdings has expanded its relationship with a global cloud provider, with major sales across multiple products in the second calendar quarter. In order to bolster both capacity and network diversity, the provider is expanding its long haul dark fiber network and upgrading optical wavelengths capacity across the U.S.
|
BKYI | Hot Stocks08:08 EDT BIO-key granted U.S. patent for biometric searching - BIO-key announced it has been issued U.S. Patent 10,025,831, "Adaptive Short Lists and Acceleration of Biometrics Database Search." The patent protects BIO-key's method of quickly and iteratively searching a database of biometric records. The method utilizes one or more scans of the database with potentially varying index parameters, narrowing the field of biometric record candidates on each pass. This 'short list' indexing approach powers BIO-key's unique advantage in delivering cost-effective one-to-many fingerprint identification solutions that avoid the costly and computer-intensive brute force scans typically required to search biometric databases.
|
CHSP | Hot Stocks08:08 EDT Chesapeake Lodging closes on sale of Hyatt Centric Santa Barbara for $90M - Chesapeake Lodging Trust announced that it has closed on the sale of the 200-room Hyatt Centric Santa Barbara located in Santa Barbara, California for a sale price of $90M, or $450,000 per key. The Trust used the net proceeds from the sale to repay all outstanding borrowings under its revolving credit facility. The Trust acquired the Hyatt Centric Santa Barbara in June 2013 for $61M, or $305,000 per key. In April 2016, the Trust sold a separate, five-room villa building and related land parcel at the Hyatt Centric Santa Barbara for $2.1M to an unrelated buyer. The $90M sale price represents a 5.4% trailing twelve month NOI cap rateand produced a 15.3% unlevered IRR over the Trust's ownership period.
|
PFS | Hot Stocks08:08 EDT Provident Financial raises quarterly cash dividend 5% to 21c per share - The Company's Board of Directors declared a quarterly cash dividend of 21c per common share payable on August 31, 2018, to stockholders of record as of the close of business on August 15, 2018. The dividend is an increase of 5% from the prior quarter's cash dividend of 20c per common share.
|
XOM | Hot Stocks08:05 EDT Exxon Mobil reports Q2 U.S. upstream net $439M, downstream net $695M - Reports Q2 international upstream net $2.6B, downstream net $29M.
|
XOM | Hot Stocks08:03 EDT Exxon Mobil reports Q2 oil-equivalent production of 3.6M barrels per day - Oil-equivalent production was 3.6 million barrels per day, down 7 percent from the second quarter of 2017. Excluding entitlement effects and divestments, liquids production increased as growth in the Permian and Bakken in the U.S. and Hebron in Canada more than offset decline and higher downtime driven by scheduled maintenance. Natural gas volumes decreased 10 percent, excluding entitlement effects and divestments, largely due to a continuing shift in U.S. unconventional development from dry gas to liquids and to downtime in Qatar, Australia, and Papua New Guinea. "Key projects in Guyana, the U.S. Permian Basin, Brazil, Mozambique and Papua New Guinea are positioning us well to meet the objectives we outlined in our long-term earnings growth plans. The high quality of these resources, combined with our strengths in project execution and innovation, will generate strong value over time," said Darren W. Woods, chairman and CEO. "Second quarter results were primarily impacted by significant scheduled maintenance undertaken to support operational integrity. In addition, while we were pleased with the return of full production following the PNG earthquake, extended recoveries from first quarter operational incidents in the Downstream were disappointing. However, good progress was made during the second quarter in fully recovering from these incidents."
|
TNXP | Hot Stocks08:02 EDT Tonix Pharmaceuticals to discontinue Phase 3 HONOR study of Tonmya - Tonix Pharmaceuticals announced that it will stop the Phase 3 HONOR study of Tonmya in military-related posttraumatic stress disorder due to inadequate separation from placebo on the primary endpoint at week 12. The primary analysis was the change from baseline in the severity of PTSD symptoms as measured by the Clinician-Administered PTSD Scale for DSM-5 between those treated with Tonmya and those receiving placebo, after 12 weeks of treatment. The Independent Data Monitoring Committee reviewed the results of the first 50 percent of participants randomized in the HONOR study and recommended stopping the trial based on a pre-specified study continuation threshold at week 12. However, meaningful improvement in overall PTSD symptoms was observed at week 4. At week 4, the Tonmya treated group separated from placebo in CAPS-5 and in the Clinical Global Impression - Improvement scale, a key secondary endpoint. Also, at week 4, sleep quality improved as measured by both the PROMIS sleep disturbance scale and the CAPS-5 sleep disturbance item, supporting the proposed mechanism of action of Tonmya. Preliminary safety data from these participants did not reveal any serious and/or unexpected adverse events and the decision to discontinue the study is not related to safety.
|
HTZ | Hot Stocks08:01 EDT Hertz appoints Opal Perry as Chief Information Officer - Hertz Global Holdings announced that Opal Perry will join the company as executive vice president and Chief Information Officer. Perry will lead Hertz's information technology strategy, development and operations, as well as the prioritization and delivery of its cloud-based systems' transformation. Perry brings more than 25 years of experience as a global technology leader. Since 2011, she has held various IT leadership positions at Allstate Insurance Company, most recently as Divisional Chief Information Officer Claims, Vice President Technology & Strategic Ventures. In that role, she has been driving industry-leading customer satisfaction for auto claims through end-to-end digital innovations and cloud-native applications and microservices.
|
TNXP | Hot Stocks07:56 EDT Tonix Pharmaceuticals trading halted, news pending
|
GT | Hot Stocks07:47 EDT Goodyear Tire CEO says 'macro headwinds are intensifying' - "We delivered strong operating performance in the quarter highlighted by impressive volume growth in our mature markets where we regained share, particularly in the more profitable 17 inch and greater rim sizes in the U.S. and Europe," said Richard Kramer, chairman, CEO and president. "Additionally, we achieved our price/mix and net cost savings goals for the quarter." "While our execution in the period was robust, macro headwinds are intensifying - including rising raw material costs, a stronger U.S. dollar and softening market conditions in China. We are adjusting our plans accordingly to mitigate the impact of these challenges over the intermediate-term. I remain confident that our strengthening position in the marketplace, along with value created through our strategic initiatives, will allow us to deliver on our 2020 plan," he added. "Our new TireHub distribution joint venture in the U.S. is performing exceptionally well out of the gate, and our shipments to the wholesale channel are running ahead of our transition plans. Goodyear's customer base has demonstrated its loyalty to our brand and I am confident that TireHub's best-in-class service model, together with added supply from our new Americas plant, will enhance value for our retail and fleet customers," said Kramer.
|
GT | Hot Stocks07:46 EDT Goodyear Tire sees FY18 segment operating income $1.45B-$1.5B - The company expects its 2018 segment operating income to total between $1.45B-$1.5B. The company has reduced its second-half outlook from the low end of the prior guidance to reflect a $130M increase in raw material costs, a $60M unfavorable swing in foreign currency due to a stronger U.S. dollar, and a $70M headwind due to softening market conditions in China.
|
ABBV | Hot Stocks07:44 EDT AbbVie sees FY18 effective tax rate approaching 9% - AbbVie's adjusted EPS guidance range reflects an effective tax rate approaching 9% in 2018. In 2018, AbbVie will experience a one-time net tax benefit related to the timing of the phase in of provisions of the new legislation on certain subsidiaries. This benefit has been excluded from the adjusted EPS guidance, and included in the GAAP guidance range. AbbVie continues to anticipate the company's adjusted effective tax rate to increase to 13% over the next five years as a result of increased domestic income and investment.
|
ABBV | Hot Stocks07:43 EDT AbbVie CEO says 'extremely pleased with the strong momentum' - "We are extremely pleased with the strong momentum of our business in the quarter and progress year-to-date. We've driven strong commercial, operational and R&D execution, resulting in top- and bottom-line results once again ahead of our expectations," said Richard Gonzalez, chairman and CEO, AbbVie. "This outstanding performance was driven by growth from several assets across our portfolio, including significant contributions from HUMIRA, IMBRUVICA, and MAVYRET. Based on our performance in the first half of the year and the tremendous confidence we have in our business, we are raising our full year 2018 EPS guidance for the third time."
|
ABBV | Hot Stocks07:42 EDT AbbVie reports Q2 global IMBRUVICA sales up 35.6% to $850M - Q2 Global HCV net revenues were $973M.
|
ABBV | Hot Stocks07:41 EDT AbbVie reports Q2 global HUMIRA sales increased 10% to $5.185B - Up 8.2% on operational basis.
|
ENDP MRK | Hot Stocks07:35 EDT Endo operating company begins shipping generic version of Merck's Invanz - Endo International (ENDP) announced that one of its operating companies, Par Pharmaceutical has begun shipping an authorized generic version of Merck (MRK)'s INVANZ, or ertapenem for injection. Endo's subsidiary, Endo Ventures recently entered into an exclusive U.S. supply and distribution agreement with a subsidiary of Merck & Co., of Kenilworth, N.J. allowing Par to launch and distribute an authorized generic of the product. According to IQVIA data, U.S. sales of INVANZ were approximately $390M for the 12 months ending May 31.
|
SAH | Hot Stocks07:34 EDT Sonic Automotive CFO says Q2 'fell short of our expectations' - Heath Byrd, the company's CFO, noted, "The second quarter of 2018 fell short of our expectations as we experienced new vehicle gross compression in several of our more significant brands. We anticipate this compression to carry into the third quarter of 2018. We remain committed to our pre-owned EchoPark brand and continue to see improvements in that segment's operating performance. Based on current performance, we will continue to expand the EchoPark brand with new stores opening in Charlotte, North Carolina and Houston, Texas in the fourth quarter of this year."
|
VRTS | Hot Stocks07:32 EDT Virtus Investment reports long-term assets under management up 3% to $89.8B - Compares to 87.4B at March 31 as a result of market appreciation and positive net flows.
|
ALNY | Hot Stocks07:19 EDT Alnylam announces CHMP recommends marketing authorization of patisiran - Alnylam announced that the Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis, or hATTR amyloidosis, in adults with stage 1 or stage 2 polyneuropathy. If approved by the European Commission, the medicine will be commercialized under the brand name Onpattro. The CHMP positive opinion is based on the evaluation of the effects of patisiran in patients with hATTR amyloidosis and its safety profile as demonstrated in the APOLLO Phase 3 study. The SmPC recommended by the CHMP includes data from APOLLO primary and secondary endpoints, as well as exploratory cardiac endpoints. The European Medicines Agency reviewed patisiran under the accelerated assessment procedure that is granted to medicines that the CHMP believes are of major interest for public health and therapeutic innovation. A CHMP positive opinion is one of the final steps before marketing authorization is granted by the European Commission. The European Commission will now review the CHMP recommendation to deliver its final decision, applicable to all 28 EU member states, plus Iceland, Liechtenstein and Norway. Patisiran is currently under priority review as a Breakthrough Therapy with the U.S. Food and Drug Administration, with an action date of August 11. Regulatory filings in other markets, including Japan, are planned for mid-2018.
|
PSXP | Hot Stocks07:17 EDT Phillips 66 Partners boosts quarterly distribution 5.3% to 75.2c - On July 18, the general partner's board of directors declared a second-quarter 2018 cash distribution of 75.2c per common unit, a 5.3% increase over the previous quarter distribution of 71.4c per common unit. The Partnership has significantly increased its distribution per common unit every quarter since its initial public offering in July 2013 and is on pace to achieve a 30 percent five-year distribution compound annual growth rate at year-end 2018.
|
IDXG CI | Hot Stocks07:12 EDT Interpace Diagnostics says Cigna covers ThyraMIR as medically necessary - Interpace Diagnostics Group (IDXG) announced yesterday morning that Cigna (CI) has agreed to cover ThyraMIR, the first microRNA gene expression classifier for thyroid nodules, as medically necessary. Interpace previously announced, in 2017, Cigna's agreement to cover ThyGenX, the company's next generation sequencing test for thyroid cancer risk assessment. ThyGenX and ThyraMIR, utilized in combination, have both high sensitivity and specificity that corresponds to clinically actionable outcomes in a single testing service, the company said.
|
TWTR | Hot Stocks07:09 EDT Twitter sees Q3 MAUs down mid-single-digit millions on sequential basis in Q3 - Twitter said: "When we suspend accounts, many of the removed accounts have already been excluded from MAU or DAU, either because the accounts were already inactive for more than one month at the time of suspension, or because they were caught at signup and were never included in MAU or DAU. We will continue to work hard to improve the health of the platform, providing updates on our progress at least quarterly, and prioritizing health efforts regardless of the near-term impact on metrics, as we believe the best driver of long-term growth of Twitter as a daily utility is a healthy conversation. As we began 2018, we made deliberate decisions to allocate product and engineering resources that had previously been focused on product improvements designed to deliver growth in audience and engagement to projects related to preparing for GDPR and broader platform health. This prioritization impacts growth in the near term, but we are confident that this is in the best long-term interest of the platform and will enable long-term growth as we improve the health of the public conversation on Twitter and over time reallocate teams from GDPR to other priorities and hire additional product and engineering resources. We may also choose to not move to paid SMS carrier relationships in certain markets where we believe we can deliver a better Twitter experience with Twitter or Twitter Lite. While the magnitude of any potential future impact is difficult to predict, DAU will not be affected because DAU only includes accounts on our owned and operated services such as the Twitter app and twitter.com. As a result of our health work, decisions not to renew or move to paid SMS carrier relationships in certain markets, and our decision to allocate resources towards GDPR and health, MAU could decline on a sequential basis in Q3. Based on our current level of visibility, we expect the decline to be mid-single-digit millions of MAU. As a reminder, DAU growth continues to be the best measure of our success in driving the use of Twitter as a daily utility."
|
DFRG | Hot Stocks07:07 EDT Del Frisco's sees FY18 total comparable restaurant sales down 1.5% to up 0.5% - Sees FY18 adjusted EBITDA $55M-$59M.
|
TWTR | Hot Stocks07:06 EDT Twitter CFO says pleased with Q2 DAU performance - "We are pleased with our performance in the second quarter in DAU growth and delivering for advertisers. We're maintaining profitability while we make investments in the business, achieving strong revenue growth and introducing product updates that make Twitter both healthier and easier to use. Looking ahead, we remain optimistic about our ability to execute on our priorities and deliver value for advertisers and shareholders," said Ned Segal, Twitter's CFO.
|
TWTR | Hot Stocks07:05 EDT Twitter sees Q3 adjusted EBITDA of $215M-$235M - For Q3, expects adjusted EBITDA to be between $215M-$235M, adjusted EBITDA margin to be between 33%-34% and stock-based compensation expense to be in the range of $85M-$90M. For FY 2018, expects stock-based compensation expense to be in the range of $300M-$350M and capital expenditures to be between $450M-$500M. Twitter notes that its outlook for Q3 and the full year 2018 reflects foreign exchange rates as of July 16.
|
COHU XCRA | Hot Stocks07:04 EDT Cohu, Xcerra announce early termination of HSR waiting period - Cohu (COHU), and Xcerra Corporation (XCRA) announced that on July 26, 2018, the Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR, with respect to Cohu's previously announced acquisition of Xcerra. The termination of the HSR waiting period satisfies one of the conditions to the closing of the acquisition as specified in the Agreement and Plan of Merger, dated as of May 7, 2018, by and among Cohu, Inc., Xavier Acquisition Corporation and Xcerra Corporation. Previously, on July 16, 2018, the Germany Federal Cartel Office granted clearance for the acquisition. In addition, Xcerra announced that its special stockholder meeting to approve the transactions contemplated by the Merger Agreement will be held on Thursday, August 30, 2018, at 9:30 a.m. Eastern time at Xcerra's corporate offices located at 825 University Avenue, Norwood, Massachusetts 02062. Cohu also announced that its special stockholder meeting to approve the issuance of shares as outlined in the Merger Agreement will be held on Thursday, August 30, 2018, at 8:30 a.m. Pacific time at Cohu's corporate offices located at 12367 Crosthwaite Circle, Poway, California 92064. The transaction is expected to close in Q4, subject to the satisfaction or waiver of customary closing conditions. Upon the completion of the proposed transaction, Xcerra's common stock will no longer be publicly traded and will be delisted from the NASDAQ Global Select Market.
|
TWTR | Hot Stocks07:03 EDT Twitter reports average daily active users up 11% year-over-year - Average daily active users, or DAU, increased 11% year-over-year, compared to 10% year-over-year growth in Q1, marking another quarter of double-digit year-over-year growth.
|
TWTR | Hot Stocks07:02 EDT Twitter reports 335M average MAUs for Q2 - Average monthly active users, or MAU, were 335M for Q2, compared to 326M in the same period of the previous year and compared to 336M in the previous quarter, reflecting impact from decisions we have made to not move to paid SMS carrier relationships, prioritizing the health of the platform, and, to a lesser extent, GDPR. Average U.S. MAUs were 68M for Q2, compared to 68M in the same period of the previous year and compared to 69M in the previous quarter. Average international MAUs were 267M for Q2, compared to 258M in the same period of the previous year and compared to 267M in the previous quarter.
|
CL | Hot Stocks06:57 EDT Colgate-Palmolive CEO says Q2 'another challenging one' - Ian Cook, Chairman and CEO, commented on the second quarter results, "The second quarter was another challenging one with category growth rates remaining soft in many markets around the world and recent unfavorable movements in foreign exchange. Net sales grew 1.5% and organic sales grew 0.5%, below our expectations, due to unit volume declines in emerging markets and flat pricing worldwide. Advertising investment increased in absolute dollars versus second quarter 2017 and we continue to plan for increased advertising investment, both absolutely and as a percent to sales, for the full year in support of new products, our base businesses and longer-term consumption-building activities. Colgate's leadership of the global toothpaste market continued during the quarter with our global market share at 42.1% year to date. Our global leadership in manual toothbrushes also continued with Colgate's global market share in that category at 32.3% year to date." Cook continued, "As we look ahead, while uncertainty in global markets and category growth worldwide remain challenging, we are maintaining our heightened focus on brand building and increased productivity while accelerating our change efforts. Based on current spot rates, we expect a low-single-digit net sales increase and low-single-digit organic sales growth in 2018, with sequential improvement in organic sales growth in the balance of the year. On a GAAP basis, based on current spot rates and including the impact of the Global Growth and Efficiency Program, we expect gross margin for the year to be even with 2017 and expect double-digit earnings per share growth versus 2017. Excluding charges resulting from the Global Growth and Efficiency Program, the one-time charge related to U.S. tax reform in 2017 and the benefit from a foreign tax matter in 2018, based on current spot rates, we are planning for a year of increased operating cash flow, modestly lower gross margin, increased advertising investment and mid-single-digit earnings per share growth versus 2017."
|
CL | Hot Stocks06:56 EDT Colgate-Palmolive reports Q2 gross profit margin 59.2% vs. 60.1% last year - Excluding charges resulting from the Global Growth and Efficiency Program in both periods, Gross profit margin was 59.3% in second quarter 2018, a decrease of 140 basis points versus the year ago quarter as higher raw and packaging material costs were partially offset by cost savings from the company's funding-the-growth initiatives.
|
TWTR | Hot Stocks06:55 EDT Twitter says it does not shadow ban following critical tweet from Trump - Twitter said yesterday in a blog post, "People are asking us if we shadow ban. We do not. But let's start with, 'what is shadow banning?' The best definition we found is this: deliberately making someone's content undiscoverable to everyone except the person who posted it, unbeknownst to the original poster. We do not shadow ban. You are always able to see the tweets from accounts you follow (although you may have to do more work to find them, like go directly to their profile). And we certainly don't shadow ban based on political viewpoints or ideology. We do rank tweets and search results. We do this because Twitter is most useful when it's immediately relevant. These ranking models take many signals into consideration to best organize tweets for timely relevance. We must also address bad-faith actors who intend to manipulate or detract from healthy conversation." President Donald Trump tweeted yesterday morning: "Twitter 'SHADOW BANNING' prominent Republicans. Not good. We will look into this discriminatory and illegal practice at once! Many complaints." Reference Link
|
TWTR | Hot Stocks06:53 EDT Twitter says it not does shadow ban following critical tweet from Trump - Twitter said yesterday in a blog post, "People are asking us if we shadow ban. We do not. But let's start with, 'what is shadow banning?' The best definition we found is this: deliberately making someone's content undiscoverable to everyone except the person who posted it, unbeknownst to the original poster. We do not shadow ban. You are always able to see the tweets from accounts you follow (although you may have to do more work to find them, like go directly to their profile). And we certainly don't shadow ban based on political viewpoints or ideology. We do rank tweets and search results. We do this because Twitter is most useful when it's immediately relevant. These ranking models take many signals into consideration to best organize tweets for timely relevance. We must also address bad-faith actors who intend to manipulate or detract from healthy conversation." President Donald Trump tweeted yesterday morning: "Twitter 'SHADOW BANNING' prominent Republicans. Not good. We will look into this discriminatory and illegal practice at once! Many complaints." Reference Link
|
CYD | Hot Stocks06:53 EDT China Yuchai establishes new subsidiary, deregisters two others - China Yuchai announced today the establishment of a new subsidiary, Guangxi Yuchai Exhaust Technology, or YETC, to design, produce and sell exhaust emission control systems for Chinese commercial vehicles to meet the highest domestic emission standard, China National VI. YETC is a wholly owned subsidiary of Guangxi Yuchai Accessories Manufacturing, or YAMC, which is a wholly owned subsidiary of Guangxi Yuchai Machinery, or GYMCL, the company's main operating subsidiary. The registered capital of YETC is RMB62M, contributed by internal funding. The new exhaust emission control systems are combination systems under China National VI, the strictest emission standard for particulates, nitrogen oxide and hydrocarbons. This emission standard corresponds to Euro 6 in Europe and EPA 10 in the USA. China National VI will result in a further reduction of 80% for nitrogen oxides and 66% for particle mass compared to the China National 5 standard. On a separate note, Nanjing Yuchai Machinery Marketing and Ningxia Yuchai Machinery Monopoly subsidiaries have been deregistered from the company Registry of the People's Republic of China by GYMCL:
|
TWTR | Hot Stocks06:53 EDT Correct: Twitter says it not does shadow ban following critical tweet from Trump - Twitter said yesterday in a blog post, "People are asking us if we shadow ban. We do not. But let's start with, 'what is shadow banning?' The best definition we found is this: deliberately making someone's content undiscoverable to everyone except the person who posted it, unbeknownst to the original poster. We do not shadow ban. You are always able to see the tweets from accounts you follow (although you may have to do more work to find them, like go directly to their profile). And we certainly don't shadow ban based on political viewpoints or ideology. We do rank tweets and search results. We do this because Twitter is most useful when it's immediately relevant. These ranking models take many signals into consideration to best organize tweets for timely relevance. We must also address bad-faith actors who intend to manipulate or detract from healthy conversation." President Donald Trump tweeted yesterday morning: "Twitter 'SHADOW BANNING' prominent Republicans. Not good. We will look into this discriminatory and illegal practice at once! Many complaints." Reference Link
|
MRK | Hot Stocks06:50 EDT Merck CEO says 'we are confident in the strength of our business' - "Strong commercial execution globally for KEYTRUDA, GARDASIL, BRIDION and other products led the company to deliver growth in the second quarter," said Kenneth Frazier, Merck Chairman and CEO. "We continue to solidify our leadership in immuno-oncology and, along with our other key pillars of growth including Animal Health, we are confident in the strength of our business."
|
MRK | Hot Stocks06:49 EDT Merck says FY18 guidance includes approximately 1% negative impact from FX
|
MRK | Hot Stocks06:48 EDT Merck sees FY18 GAAP effective tax rate 23%-24%
|
JMP | Hot Stocks06:46 EDT JMP Group closed $407.8M collateralized loan obligation - JMP Group announced the closing of a $407.8M collateralized loan obligation, or CLO, transaction issued by two newly formed special purpose vehicles and backed by a diversified portfolio of broadly syndicated leveraged loans. The notes offered in the transaction are issued by JMP Credit Advisors CLO V Ltd. and co-issued in part by JMP Credit Advisors CLO V LLC and are subject to a two-year non-call period.
|
TWTR | Hot Stocks06:40 EDT Twitter says it does shadow ban following critical tweet from Trump - Twitter said yesterday in a blog post, "People are asking us if we shadow ban. We do not. But let's start with, 'what is shadow banning?' The best definition we found is this: deliberately making someone's content undiscoverable to everyone except the person who posted it, unbeknownst to the original poster. We do not shadow ban. You are always able to see the tweets from accounts you follow (although you may have to do more work to find them, like go directly to their profile). And we certainly don't shadow ban based on political viewpoints or ideology. We do rank tweets and search results. We do this because Twitter is most useful when it's immediately relevant. These ranking models take many signals into consideration to best organize tweets for timely relevance. We must also address bad-faith actors who intend to manipulate or detract from healthy conversation." President Donald Trump tweeted yesterday morning: "Twitter 'SHADOW BANNING' prominent Republicans. Not good. We will look into this discriminatory and illegal practice at once! Many complaints." Reference Link
|
MGLN | Hot Stocks06:33 EDT Magellan Health lowers FY18 outlook
|
PSO | Hot Stocks06:29 EDT Pearson says simplification plans 'on track' - Pearson says cost savings of GBP 40m delivered in the first half, decommissioned over 200 applications and started the implementation of our new Enterprise Resource Planning software system in the US. Says the US K12 courseware business continues to be held for sale.
|
DANOY | Hot Stocks06:25 EDT Danone backs view of double digit recurring EPS growth in FY18 - Danone assumes that market volatility will continue. In 2018, Danone expects further cost-inflation with a mid-single digit rise in the costs of raw and packaging materials, including: milk price inflation of low to mid-single digit overall, a double-digit increase of PET pricing driven by the crude oil price rebound and, inflationary conditions in other raw materials, including sugar and fruits. Danone also expects an ongoing impact from currency volatility, particularly the UK pound. Danone's focus will remain on accelerating growth and maximizing efficiencies, including the first year of delivery of its Protein program's savings. In 2018, the company will progress towards its 2020 ambition through further sales growth and an improved recurring operating margin.
|
HF | Hot Stocks06:17 EDT HFF sells three Class A industrial buildings in Countyline Corporate Park - Holliday Fenoglio Fowler announces the sale of three newly constructed, fully-leased, Class A, trophy industrial buildings in Countyline Corporate Park totaling approximately one million square feet in the Miami MSA. HFF marketed the property on behalf of the seller, Flagler Global Logistics, a wholly-owned subsidiary of Florida East Coast Industries. Duke Realty purchased the asset free and clear of existing debt. Countyline Corporate Park is Miami-Dade County's newest business park and will ultimately contain up to 8M square feet of commercial space within approximately 500 acres. The HFF investment advisory team representing the seller included managing directors Luis Castillo and Adam Herrin, executive managing director Manny de Zarraga, senior managing directors Rusty Tamlyn and Coleman Benedict and director Tracey Goo.
|
TPH | Hot Stocks06:07 EDT TRI Pointe reaffirms FY18 average selling communities view o up 5% vs last year - Reaffirms guidance view of delivering between 5,100 and 5,400 homes. The Company is increasing its expected average sales price for the full year to $625,000 from $610,000. The Company continues to expect its homebuilding gross margin percentage for the FY18 to be in the range of 21.0% to 21.5%, SG&A expense as a percentage of home sales revenue to be in the range of 9.9%-10.3% and its effective tax rate to be in the range of 25%-26%.
|
TPH | Hot Stocks06:05 EDT TRI Pointe sees Q3 gross margin percentage 21.0%-21.5% - Expects to open 15 new communities, and close out of 17 in Q3, resulting in 128 active selling communities as of September 30. In addition, the Company anticipates delivering 50%-55% of its 2,271 units in backlog as of June 30 at an average sales price of $630,000. Finally, the Company expects its SG&A expense as a percentage of home sales revenue to be in the range of 10.8%-11.2%.
|
GWR | Hot Stocks06:02 EDT Genesee & Wyoming CEO says outlook for 2H18 'remains promising' - Jack Hellmann, Chairman, President and CEO of G&W, commented, "Our reported financial results for the second quarter of 2018 of $0.73 per diluted share were generally consistent with the second quarter of 2017, primarily because of our previously announced U.K. restructuring charges. Our adjusted diluted EPS of $0.94 for the second quarter of 2018 were at the high end of our outlook as business conditions continued to improve in each of our three geographies, led by North America. Our same railroad carloads increased 8% in North America with particular strength in coal, steel and minerals and stone traffic. While our operating leverage in North America during the quarter was adversely impacted by several variables including the mix of business, the lag in fuel surcharge recovery, and legal fees associated with an arbitration proceeding, we expect to see our customarily strong operating leverage for the remainder of 2018 based on our current volume outlook. In Australia, our second quarter results were as expected with particular growth in our spot coal traffic due to the early delivery of a new train set. In the UK/Europe, we successfully initiated our restructuring activities and achieved financial results that were ahead of our expectations. Our business outlook for the remainder of 2018 remains promising thanks to growing customer demand for rail shipments across most commodity groups, particularly in North America. In addition, we have refinanced our senior credit facility with improved terms through 2023, we have more than $600 million of capacity under our revolving credit facility, and we continue to evaluate investment opportunities in multiple markets including the opportunistic purchase of our own shares."
|
WY | Hot Stocks05:48 EDT Weyerhaeuser sees Q3 Timberlands earnings, adj. EBITDA lower than Q2 - Weyerhaeuser expects Q3 Timberlands earnings and Adjusted EBITDA will be lower than the second quarter, but slightly higher than the third quarter of 2017. The company anticipates seasonally higher road and forestry costs and higher fuel and unit logging costs. In the West, average sales realizations are expected to be slightly lower than the second quarter and fee harvest volumes will be comparable. In the South, the company anticipates higher fee harvest volumes and comparable average log sales realizations. Weyerhaeuser anticipates Q3 Real Estate, Energy & Natural Resources earnings and Adjusted EBITDA will be higher than the second quarter. Weyerhaeuser continues to expect full year 2018 adjusted EBITDA for the segment will be approximately $250 million. Weyerhaeuser expects Q3 Wood Products earnings before special items and Adjusted EBITDA will decrease compared with the second quarter. The company anticipates moderately lower average sales realizations for lumber and oriented strand board. As previously disclosed, sales volumes for oriented strand board will be lower due to an extended outage at our Grayling, Michigan mill for a scheduled press replacement.
|
TKR | Hot Stocks05:35 EDT Timken acquires Rollon, expects deal to be accretive to earnings in first year - Timken has reached an agreement with pan-European firm Chequers Capital and IGI Private Equity to acquire Rollon Group. Rollon specializes in the design and manufacture of linear guides, telescopic rails and linear actuators used in a wide range of industries such as passenger rail, aerospace, packaging and logistics, medical and automation. Rollon sales are expected to be about $140M for the full year 2018. Timken expects the acquisition to be accretive to earnings in the first year of ownership. The transaction, which is subject to customary regulatory approvals, is expected to close in late September 2018 and will be funded with debt.
|
BABA | Hot Stocks05:22 EDT Alibaba cloud continues to invest in Malaysia - Alibaba Cloud, the cloud computing arm of Alibaba Group, announced the launch of their second availability zone in Malaysia to expand its cloud footprint and bolster its cloud capacity, serving increasing customer demand locally and in the region. The new zone complements Availability Zone A which was launched last year in heightening cloud security and ensuring business continuity through resilient cloud infrastructure. Alibaba Cloud will also continue to invest in Malaysia by setting up the first cloud based Anti-DDoS Scrubbing Center in August. The center will mitigate risks and offer customers the highest level of protection against stronger DDoS attacks. The new center will feature a variety of security functions including Anti-DDoS Pro, a service that defends against all types of DDoS attacks.
|